GlaxoSmithKline News and Research

RSS

Study shows possible solution to the current flu vaccine shortage

A new study led by the Saint Louis University’s Center for Vaccine Development may provide a solution to the current flu vaccine shortage in the U.S. The team found a possible way to double the available supply of influenza vaccine for adults between the ages of 18 and 60.

4 Nov 2004

Human Genome Sciences announces agreement with GSK for development of drug to treat diabetes

Human Genome Sciences today announced an agreement with GlaxoSmithKline under which GlaxoSmithKline has acquired exclusive worldwide rights to develop and commercialize Albugon (albumin-glucagon-like peptide-1, GLP-1), a drug currently in late-stage preclinical development by Human Genome Sciences for potential use in the treatment of diabetes.

26 Oct 2004

Discovery might improve design, effectiveness of anti-cancer drugs

Working with an enzyme that degrades anti-cancer drugs in humans, University of North Carolina at Chapel Hill biochemists and colleagues have made a discovery that they believe eventually could help improve such drugs’ design and effectiveness.

18 Oct 2004

Glaxo drops appeal in AIDS drug pricing case

A landmark South African legal complaint against British drug maker GlaxoSmithKline (GSK) over its AIDS drug pricing and policies in that country will proceed after GSK dropped its public and repeated vows to appeal a decision allowing the case to go forward.

22 Sep 2004

GlaxoSmithKline has granted a voluntary licence to Cosmos Limited for the manufacture and sale of antiretrovirals

GlaxoSmithKline currently sells zidovudine (sold as Retrovir®), lamivudine (sold as Epivir®) and the combination of the two molecules (sold as Combivir®) across the region.

22 Sep 2004

Bonviva, to treat osteoporosis, submitted for marketing authorisation in Europe

Roche and GlaxoSmithKline announced today the submission of a Marketing Authorisation Application to the European authorities for a novel, once-monthly oral formulation of their new bisphosphonate, Bonviva (ibandronate), for the treatment of postmenopausal osteoporosis.

20 Sep 2004

Crucell and AIDS Vaccine Initiative have signed an exclusive license agreement to develop an AIDS vaccine

Dutch biotechnology company Crucell and the International AIDS Vaccine Initiative (IAVI) have signed an exclusive license agreement to develop an AIDS vaccine based on Crucell’s AdVac® technology.

20 Sep 2004

Prozac, Paxil, Wellbutrin, Zoloft, Celexa, Effexor, Luvox and Remeron should have "Black Box" warnings

A panel of experts has voted 15 to 8 in favour of the Federal Food and Drug Administration (FDA) adding black box warnings to certain medications used to treat depression in children and teenagers.

14 Sep 2004

Schering-Plough and Bayer form strategic alliance

Schering-Plough Corporation has announced that it has entered into a strategic agreement with Bayer designed to maximize the companies' pharmaceutical resources while maintaining each company's own strategic interests.

13 Sep 2004

Researchers have produced a marathon mouse that can run twice as far as normal mice

By enhancing the function of a single protein, Howard Hughes Medical Institute researchers have produced a “marathon mouse” with altered muscle composition and enough physical endurance to run twice as far as normal mice.

23 Aug 2004

Failing to disclose the results of clinical trials kills patients

Failing to disclose the results of clinical trials kills patients and wastes money, and government regulation is needed to put a stop to it, argues Sir Iain Chalmers in a letter to this week's BMJ.

20 Aug 2004

Researchers study whether people’s genetic makeup could make them more likely to develop osteoarthritis of the knee and hip

Researchers at The University of Nottingham are studying whether people’s genetic makeup could make them more likely to develop osteoarthritis of the knee and hip — the most common medical condition to affect the joints.

3 Aug 2004

FDA approval for mint flavor nicotine gum

Watson Pharmaceuticals announced today that it has received approval from the United States Food and Drug Administration on its Abbreviated New Drug Application for nicotine polacrilex gum, mint flavor, in the 2 and 4 mg strengths.

3 Aug 2004

Drug to fight virus from the herpes family in transplant patients moves forward in trials

A drug once considered for cancer chemotherapy is advancing in clinical trials to test its effectiveness in fighting a virus from the herpes family that threatens transplant patients.

29 Jul 2004

GlaxoSmithKline to stand trial on AIDS drugs

The Competition Tribunal of South Africa agreed late last week to hear the complaint filed by individual South Africans and AIDS Healthcare Foundation, a nongovernmental organization that operates a free AIDS treatment clinic in Durban, that British drug maker GlaxoSmithKline illegally excessively priced AIDS drugs in violation of the South African Competition Act.

26 Jul 2004

Court ruling favors State over pharmaceutical manufacturers

Nevada Attorney General Brian Sandoval yesterday announced that Washoe County District Court Judge Steven R. Kosach has issued an important ruling in Nevada's Average Wholesale Price (AWP) litigation against numerous pharmaceutical manufacturers including Abbott Labs, Baxter, Bristol-Myers Squibb, Dey, GlaxoSmithKline, and Pharmacia.

21 Jul 2004

AIDS Healthcare Foundation targets GSK over voluntary licensing of its AIDS drug patents in South Africa

At the international AIDS conference in Bangkok, AIDS Healthcare Foundation hosted a peaceful protest against British multinational pharmaceutical giant GlaxoSmithKline over its voluntary licensing of its AIDS drug patents in South Africa.

13 Jul 2004

New guidelines for pulmonary arterial hypertension caution the use of calcium channel blockers

A new evidence-based guideline for pulmonary arterial hypertension (PAH) cautions the use of calcium channel blockers, a commonly used treatment for high blood pressure, in unstable patients due to the potentially fatal side effects associated with the medication.

13 Jul 2004

Study evaluates effectiveness of LEXIVA/ritonavir and Lopinavir/ritonavir in protease inhibitor

HIV treatment regimens containing the protease inhibitor (PI) LEXIVA® (fosamprenavir calcium) dosed with ritonavir (LEXIVA/r) or lopinavir (LPV) and ritonavir (LPV/r) were effective in suppressing HIV in patients who had failed prior PI-containing regimens, according to information presented at the International AIDS Conference (IAC).

12 Jul 2004

GSK and Boehringer Ingelheim to develop treatment for HIV infection specifically for the developing world

GlaxoSmithKline and Boehringer Ingelheim announced today that the companies have signed a letter of intent for an accelerated development programme for a co-package for Combivir® (lamivudine/zidovudine) and Viramune® (nevirapine) for chronic treatment of HIV infection in the developing world.